PD-1 and PD-L1 Antibodies in Lung Cancer
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.
Read about predictive biomarkers ofPD-1 pathway blockade
Articles in this issue
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma
MPDL3280A Induces Durable Responses in NSCLC, Other Cancers
Immunotherapy—An Increasingly Important Role in Oncology
Suzanne Topalian, MD, on PD-1 Targeted Therapy
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhD
PD-1 and PD-L1 Antibodies in Lung Cancer
Checkpoint Inhibitors in Cancer Care
Search for Predictive Biomarkers of PD-1 Pathway Blockade
Nivolumab Plus Ipilimumab in Advanced Melanoma
The Outlook for Immunotherapies
Recent Videos
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024Article
During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
